-
公开(公告)号：EP3845524A1
公开(公告)日：2021-07-07
申请号：EP19772121.0
申请日：2019-03-14
发明人： CHANG, Junbiao , DU, Jinfa , ZHU, Kaikai , WANG, Kai
IPC分类号： C07D307/88 , C07C65/01 , C07C51/41 , A61K31/365 , A61K31/192 , A61K9/20 , A61K9/48 , A61K9/19 , A61P9/10 , A61P25/08
摘要： The present invention belongs to the field of medicinal chemistry, relates to novel benzoic acid compounds I and II, and relates to the applications thereof in prevention and treatment or remission of cerebral ischemia or ischemia after acute and chronic myocardial infarction. In the structures of compounds I and II, X is H, I, Br, Cl, F, CN, amino and derivatives thereof. R 1 is the alkyl of C 2-10 , which is substituted for C 2-10 alkyl, except for N-butane; M is an organic amine ion or a metal ion.
-
公开(公告)号：EP3954682A1
公开(公告)日：2022-02-16
申请号：EP19924592.9
申请日：2019-04-09
发明人： CHANG, Junbiao , DU, Jinfa , ZHU, Kaikai , WANG, Kai , LI, Jianyong , ZHANG, Chunxia , YI, Dongxu
IPC分类号： C07D403/04 , A61P35/00
摘要： The present invention discloses a new anti-lung cancer medicine, and specifically relates to a 2-(2,4,5-substituted phenylamino)pyrimidine derivative I and a crystal form B thereof, belonging to the field of medicinal chemistry. The derivative has the following structure: (1). According to the results of pharmacokinetic and pharmacodynamic research, doxitinib significantly reduces the production of a metabolic product N-Me with a greater toxicity, and maintains or improves the efficacy in comparison to osimertinib. Doxitinib is expected to be developed as a safer and more effective novel medicine for the treatment of non-small cell lung cancer with EGFR mutation in comparison to osimertinib.
-
公开(公告)号：EP4112050A1
公开(公告)日：2023-01-04
申请号：EP21760199.6
申请日：2021-02-20
发明人： CHANG, Junbiao , DU, Jinfa , JIANG, Jiandong , LI, Yuhuan
摘要： Use of a compound represented by formula (I) or pharmaceutically acceptable salts thereof in the preparation of a medication for preventing or treating a coronavirus infectious disease. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in all of the clearance rate by viral nucleic acid test, the course of clearance, and the cure and discharge time.
-
4.发明公开
公开(公告)号：EP3567043A1
公开(公告)日：2019-11-13
申请号：EP17889767.4
申请日：2017-12-21
发明人： CHANG, Junbiao , DU, Jinfa
IPC分类号： C07D495/04 , A61K31/519 , A61P35/00
摘要： The present invention provides a thienopyrimidinone derivative, a preparation method thereof, and an application thereof in manufacturing of antitumor drugs. The derivative has a structure as represented by general formula (I), comprising a single stereoisomer or racemic mixture thereof, wherein R is independently selected from hydrogen (H) or deuterium (D); R 1 and R 2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N 3 , and when R represents H, R 1 and R 2 do not synchronously represent H; R 3 , R 4 and R 5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.
-
5.发明公开
公开(公告)号：EP3939984A1
公开(公告)日：2022-01-19
申请号：EP19920547.7
申请日：2019-04-18
发明人： CHANG, Junbiao , DU, Jinfa , YI, Dongxu
IPC分类号： C07H19/06 , A61K31/7068 , A61K31/7076 , A61P31/18
摘要： Disclosed is a crystal form A of a 2'-fluoro-4'-substituted nucleoside analog I, wherein same falls within the field of pharmaceutical chemistry. The crystal form A has the following structure: (I). The CuKα-XRPD pattern of the crystal form A of the compound I is as shown in figure 2 , wherein the crystal form A has a good stability and can easily be uniformly mixed with auxiliary materials. The crystal form A of the compound I is mixed with the auxiliary materials, so that the uniformity thereof in tablets is increased, and same is conducive to controlling the drug quality and ensuring the drug efficacy. The crystal form A is used for preparing anti-HBV or anti-HCV or anti-HIV drugs or anti-tumor drugs.
-
-
-
-
搜索结果
5 条记录 (耗时 0.01 秒)
